Skip to main content
. 2016 Oct 18;4(4):446–462. doi: 10.1002/iid3.126

Figure 7.

Figure 7

Activation profiles of dSLIM:ProMune chimeras. PBMC were treated with the indicated molecules at final concentrations of 3 μM or with medium alone for 48 h. dSLIM2006‐PD comprises the base sequence of ProMune® in both loop structures of dSLIM® linked by phosphodiester bonds; dSLIM2006‐PTO comprises the base sequence of ProMune® in both loop structures of dSLIM® linked by PTO bonds. Statistical evaluations for the comparisons between both dSLIM2006 molecules and ProMune® as well as between dSLIM2006‐PD and dSLIM® are shown. (a) Cytokine secretion: cytokine levels in the supernatants were determined by a bead‐based multiplex immunoassay or ELISA (IFN‐α, IFN‐γ, IP‐10, IL‐8 n = 17, means are shown, *P < 0.05, **P < 0.01, *** p < 0.001, NS, not significant; repeated measures ANOVA, Fisher's LSD test). (b) Cellular activation pattern: cells were stained with antibodies against lineage‐ and activation markers, and analyzed by flow cytometry as described in Materials and Methods section. Frequencies or MFI of activation markers within the cell populations are shown (n = 17, means are shown, *P < 0.05, **P < 0.01, ***P < 0.001, NS, not significant; repeated measures ANOVA, Fisher's LSD test).